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Abstract
This article focuses on issues concerning science and technology relationships posed by the
emergence of a new drug discovery method, namely, combinatorial chemistry and biology.
We assess the scientific content of combinatorial chemistry and biology using citations in
patents to scientific journals and compare this research platform with biotechnology. We
also identify the institutional affiliation of all the authors of the cited papers, which leads us
to an analysis of knowledge spillovers between the main participants in the research
network. Finally, we examine the relevance of localisation in the process of knowledge
exchange with regard to EU countries and the US. The result of the analysis provide
evidence to support the view that the inventive capacity of a country is dependent upon the
basic research which is carried out, especially in universities and public research centres
located in the inventor’s country.3
1. Introduction
Recent work in the economics of science and technological change as well as in science and
technology studies has revived interest in the contribution of publicly funded research to
industrial innovation.
1 Such interest has led to the expansion of better measurements, a
development that largely stems from the availability of new databases of science and
technology indicators combined with the development of powerful desktop computers and
new software. Broadly speaking, scholars attempting to gauge the contributions of publicly
funded research to industrial innovation have followed three methodological paths: (1)
econometric studies, (2) survey and (3) case studies. Diversified though these methods may
be, they have set the stage for a better theoretical understanding of the science-technology
relationship and thereby contributed to easing the task of policymakers.
Although the studies that have applied these methodological tools share the general
conclusion that public research may be a prime factor behind technological change and
economic growth, it does not follow that technological change will necessarily generate
economic growth. Thus, the picture that emerges can in no way be taken as being a map of
all inventive activities. In other words, publicly funded research may well be conducive to
more industrial innovations but will not yield evenly across technological sectors.
In this context, a quantitative assessment of the science-technology linkages
characterising combinatorial chemistry and biology, an emerging research platform that
spans a broad spectrum of applications from drug to new materials discoveries, should be
well received. Embedded in a large network of firms, universities and research centres,
combinatorial synthesis methods, albeit still in their infancy, are bound to be a spawning
grounds for a stream of new products. However, despite its tremendous potential, no study
has ever tried to examine the issue of public research and its contribution to combinatorial
innovations. The purpose of this paper is to fill this void.
The paper is organised as follows. Section 2 presents a brief technical and historical
account of combinatorial synthesis methods, including parallel synthesis techniques,
solution-phase methods and combinatorial biology, and discusses the improvements in
                                                          
1 For an exhaustive review of the literature on the economic benefits of publicly funded basic research see4
price and performance that have been associated with their uses in drug discovery
processes. Section 3 focuses on linkages with science. Responding to the drive for new
insights, we began by constructing three comprehensive databases, covering all the patents,
firms and publications in combinatorial chemistry and biology for the period 1980-1997.
Using the CHI classification of journals from applied technology to basic research, we then
analysed the scientific content of patents in combinatorial chemistry and biology to shed
light on the principal fields of science cited by combinatorial patents. In Section 4, we
explore the distribution of author institutions to identify the contribution of science to
innovation and, finally, examine the question as to whether or not localisation affects the
science-technology linkages. Section 5 provides concluding remarks and suggestions for
further research.
2. An overview of combinatorial chemistry and biology methods
Combinatorial synthesis methods are here defined as “the systematic and repetitive,
covalent connection of a set of different ‘building blocks’ of varying structures to each
other to yield a large array of diverse molecular entities” (Gallop et al. 1994:1233). These
technologies encompass a broad range of methodological schemes, the diversity of which
reflects whether the building blocks are amino-acids, small chemical molecules, DNA or
RNA; whether the synthesis of molecules is applied in solution, on a solid substrate or a
biological system (i.e. living micro-organisms or preparations thereof such as phages,
bacterial cells or DNA binding proteins); whether molecules are screened one at a time or
simultaneously in a mixture; whether the biological target (i.e. molecular site of
intervention) is known or unknown; whether the techniques are used for lead discovery (i.e.
process of finding one or more compounds which interact with the target) or lead
optimisation (i.e. process of synthesising variations of the lead compound); and so on. Yet,
despite this diversity, there is little risk of over-categorising the various combinatorial
synthesis methods if a clear distinction is established between the methods of solution-
phase synthesis, parallel synthesis and combinatorial biology.
                                                                                                                                                                                
Martin et al. 1996.5
The first combinatorial method - solution-phase synthesis - was pioneered in 1982
by Árpád Furka at Eötvös University in Budapest (Hungary) (Furka 1995; Borman 1997).
His "portioning-mixing" method, equally known as the split synthesis technique or the
"divide, couple, and recombine" process, is most commonly carried out by tethering amino-
acids to microparticles or polymer beads in a given number of vessels, say 3, one for each
molecule. After thorough washing to remove excess reagents, these chemical units are then
combined and mixed in a single dish and again separated in equal portions into 3 additional
vessels. At this stage, different sets of new building blocks are added to the vessels to
produce 9 different novel compounds. The protocol can be repeated as often as needed. In
this example, the combinatorial procedures are simply reproduced a third time, yielding 27
new molecular entities. However, a more realistic combinatorial project using 20 different
building blocks and involving a five-fold reproduction would create 205 different chemical
combinations, or 3.2 million new compounds, each exhibiting different chemical properties
(Terrett et al. 1995; Gordon et al. 1996; Furka et al. 1991).
Next came the parallel synthesis technique, which was invented by a group of
scientists led by Mario Geysen (Geysen et al. 1984)
2 at the Australian pharmaceutical
company Commonwealth Serum Laboratories in 1984. Schematically, combinatorial
chemists using this technique would perform a series of individual reactions separately but
simultaneously in the different reaction vessels of (usually) a microtitre plate (i.e. a
moulded plastic sheet of wells filled with a few millilitres of reagents). Most scientists
would begin the process by anchoring a given set of building blocks to pin-shaped
polystyrene beads and inserting the resulting chemical unit-plastic bead combination into
the wells of the first row, which would then be thoroughly filtered in order to wash away
unreacted chemicals, that is to say, those not connected to the beads. These operations
would be repeated with different sets of molecules in the wells of the other rows. Upon
completion, a further set of building blocks is added to the first column, another one to the
second, and so on. Unreacted chemicals are once again filtered away and the resulting
compounds screened for biological activity (Plunkett and Ellman 1997). On the basis that
                                                          
 2 It should be stressed, however, that variants of such a technique appear in parallel in many laboratories
throughout the world, including the cellulose paper procedure by Frank et al. (1983) in Germany and the
``tea-bag`` approach by Richard Houghten (1985) in the United States. Not surprisingly, the paternity of
combinatorial chemistry remains very doubtful (Lebl 1998).6
microtitre plates typically contain 96 wells (i.e. 12 columns and 8 rows), a collection of 96
different new compounds could be synthesised in this way in a matter of hours, if not
minutes.
Another milestone in the history of drug discovery processes concerns
combinatorial biology, which was the brainchild of George Smith of the University of
Missouri (US) in 1985 (Smith 1985). Combinatorial biology allows peptide libraries to be
created with the help of molecular biology and some of the principles, rules of thumbs,
methodologies and instruments otherwise associated with combinatorial chemistry. In a
nutshell, scientists have invented an array of methods by which different sets of nucleic
acids are randomly synthesised and subsequently inserted into biological systems, which in
turn transcribe and translate the encoding genetic information into a vast number of
different peptides.
These three methods, which set the stage for numerous incremental process
innovations including the light-directed synthesis method (Fodor et al. 1991), the
Diversomer technique (DeWitt and Czarnik 1995), the ‘orthogonal synthesise  approach
(Deprez et al. 1995), have only just begun to grab the attention of policy-makers. Yet these
technologies have sparked the interests of many entrepreneurs, who have founded small
start-up companies in order to exploit these technologies, and large pharmaceutical
companies, which have quickly built-up in-house capabilities (Glaser 1995; Brown 1996).
Such companies have embarked on the combinatorial bandwagon for a variety of reasons.
The first reason revolves around the fact that combinatorial chemistry and biology
offer a solution to the innovation deficit of the industry. Thus, in contrast to the orthodox
chemical approach, which was devoted to yielding one pure substrate at a time in an
individual test tube, combinatorial synthesis (or molecular diversity, as it is often called)
allows the creation of vast in-house collections of molecular compounds, also known as
combinatorial libraries. By combining mixtures of substances in tiny amounts in a selective
and precise way, drugmakers are capable of producing molecular entities in previously
inconceivable quantities. Up to 1991 the chemical literature described no more than an
estimated 11 million compounds, a paltry performance by today's standards considering7
that a small team of combinatorial chemists may now easily exceed this number in less than
a week (Lowe 1995)
3.
A second reason lies with the fact that combinatorial synthesis methods have also
recently moved from the pharmaceutical sector into the realm of new materials; thus, they
are helping to create not only new therapeutic drugs but also new catalysts, polymers,
lubricants, and agrochemical products (Service 1998; Borchardt 1998; Stix 1998). For
example, combinatorial chemists at the California-based combinatorial synthesis firm,
Symyx, have been able to construct and screen a library of more than 25,000 different new
light-emitting materials. Having discovered a blue phosphore that is entirely different from
other light-emitting materials, their concerted efforts are directed towards optimising this
discovery, an endeavour that could lead to applications in television and computer screens
(Service 1998).
Finally, and perhaps more importantly, the new "shotgun" method of discovering
therapeutic drugs (and new materials) has been a boon as far as the prospects of improving
R&D efficiency are concerned. An illuminating illustration of this is presented by Thomke
et al. (1998) in a field study about a combinatorial drug discovery program that aimed at
treating glaucoma. Using data provided by the combinatorial synthesis firm, Pharmacopeia,
a leader in the industry, the authors found that 4 combinatorial chemists had created 9000
drug-like molecules for less than $US 19 each, a radical reduction considering that 15
chemists using traditional synthesising methods would have synthesised about 3,500
compounds at a price of $US 5,000 per unit. Similarly, combinatorial methods have
reduced development time to some three and half months, as compared to the estimated five
years it would have typically taken using conventional medicinal chemistry.
The account of the evolution of combinatorial synthesis and description of its
impact on the drug discovery process presented above, clearly underscores the growing
importance of combinatorial chemistry and biology as a new emerging research platform in
the pharmaceutical industry. To our knowledge, a detailed analysis of the scientific and
technological network underlying combinatorial chemistry and biology has not yet been
                                                          
3 While combinatorial chemistry and biology have yet to yield a single product, dozens of combinatorial drugs8
undertaken. The following two sections are devoted to this exercise. Central to our concern
will be the scientific and technological relationships that characterise research activities in
universities, research institutions, and small, medium and large sized firms.
3. The scientific content of combinatorial chemistry and biology patents
Although there is wide agreement among scholars and practitioners on the contribution of
public research -i.e. scientific research performed at public research institutes and
universities- to the process of industrial innovation, different and sometimes conflicting
measures of the relevance of its contribution have been proposed (Martin et al. 1996; Smith
and Barfield, 1996). Another methodological difficulty that has come to the fore of this
debate is that generalisations about the effects of fundamental science on applied research
and other stages of the innovation process are virtually impossible to support. One simple
but powerful reason for this is that linkages between science and technology vary greatly
across industrial sectors. This is amply confirmed by a series of scientometric studies,
wherein patent citations have been examined to reveal signs of science dependence
(Carpenter et al. 1980; Narin 1985; Collins and Wyatt 1987; Narin and Olivastro 1991;
Godin 1995; Anderson et al. 1996; Narin, Hamilton and Olivastro 1997; Verspagen 1998).
Such studies have drawn attention to how innovations in firms depend on science
and thereby public research in different ways. Most of them were carried out by CHI
Research Inc. or were at least largely inspired by its methodology. To understand how
CHI’s analytical apparatus can be employed in accounting for science and technology
linkages, it is important to recall that patent data contain references to existing patents and
mainstream literature. This means that the citations in patents to journal papers of specific
technologies or industrial sectors can be extracted from the patent database for further
analysis. In particular, one can learn more about the underlying research science base of a
particular technology or industry by categorising citations in patents to literature according
to a classification produced by CHI, which breaks down several thousand journals covered
by the Science Citation Index into four different levels:
                                                                                                                                                                                
are currently awaiting approval by the regulatory agencies (Hughes 1996).9
·  Level 1: Applied technology (e.g. Journal of Urology)
·  Level 2: Engineering and technological sciences (e.g. Chemical & Engineering News)
·  Level 3: Applied research (e.g. Journal of Chromatography)
·  Level 4: Basic research (e.g. Nature, Journal of the Chemical Society)
Once citations are classified along these lines, science and technology linkages may
be traced by looking at the extent to which basic research journals are being cited as prior
art for a given technology/industry. Underlying this reasoning is that patents granted in
science-based industries ought to cite basic research journals more frequently than patents
in other industrial sectors. In this context, the legitimate question that arises is whether
combinatorial patents include a high level of scientific content, i.e. a high proportion of
citations to patents in basic research journals.
The patent, publication, citation in patent and firm databases
To answer the above question, the exact procedures of the CHI methodology had to be
reproduced using: i) a set of European Patent Office (EPO) patents dealing with
combinatorial innovations and; ii) CHI’s classification of journals. As data on
combinatorial chemistry and biology have been noticeably scarce, a patent database had to
be constructed from scratch. Such an enterprise was fraught with difficulties. Therefore, it
was not until 1992 that the term “combinatorial” begin spreading into the patent system, the
year a patent entitled “Combinatorial strategies for polymer synthesis” (EP 0624059 - A1)
was granted to the California-based combinatorial synthesis firm, Affymax. To circumvent
this problem, a series of keywords such as “parallel synthesis”, “split synthesis” “chemical
library” and “oligonucleotide library”, in addition to the term “combinatorial”, had to be
used. However, even then the use of such combinatorial jargon was not sufficient. Hence
the database had to be solidified by the building of another two databases. The first was on
firm formation and the second one on scientific publications. Moreover, a publication
database has the merit of providing a point of comparison with the citation database, a point
that will be treated more extensively in Section 4. Complex though this exercise is,
retrieving information on combinatorial chemistry and biology both from the Internet and
the CD-roms of the Institute for Scientific Information proved to be helpful as newly-
founded firms and scientific articles often revealed new combinatorial patents. More10
precisely, an iterative process was used to consolidate all three databases. An Internet
discovery of a new company would lead to a new patent and publication search, whereas
patent and bibliometric data often exposed yet more corporate information. In this
connection, a netsite entirely dedicated to combinatorial chemistry (www.5z.com) turned
out to be a particularly useful source of information, listing combinatorial synthesis
companies and scientists as well as papers and patents.
Having said this, our endeavours uncovered 220 small combinatorial chemistry and
biology start-ups, 1165 patent applications
4, which spanned the period 1985-1997, as well
as 2,570 scientific publications that were released between 1984 and 1996 (see Figure
1).Not surprisingly, the Commonwealth Serum Laboratories, the Australian company
where Mario Geysen originally worked, was one of the first to enter the field 1) by
establishing in 1988 the first combinatorial chemistry and biology company, a subsidiary
named Coselco Mimotopes
1e 1 It is worth remarking that Commonwealth Serum Laboratories resolved
to sell Coselco Mimotopes (now Chiron Mimotopes) to Chiron in 1996. The decision was taken on the
grounds that combinatorial chemistry and biology did not fit its strategic plan , CSL being essentially a
biotechnology company seeking to develop biological products (Personal communication, Ian Gust, Director
of CSL, September 7, 1998).; 2) by patenting Geysen’s new synthesis method in 1986; and 3) by






















publishing a paper in the well-established  Proceedings of the National Academy of
Sciences in the USA in 1984. Interestingly enough, this initial paper was rejected by the first
scientific journal it was submitted to. The reviewers' decision was grounded on the apparent
discrepancy between theory and empirical data; thus, it was argued that combinatorial
chemists could not rigorously predict the number and amount of newly produced molecular
compounds (Baum 1994).
That the emergence of combinatorial chemistry and biology start-ups is a recent
trend can be captured by the fact that 127 combinatorial synthesis firms, or 58% of the
total, were founded from 1992 onwards. Also worthy of note is the observation that the US
leads the pack in terms of firm formation, with 170 firms offering their services in
combinatorial synthesis, followed by Britain (18 firms), Germany (8), Canada (6), France
(3), Australia (6), France (3), Denmark (2) and Sweden (2). This is instructive in that the
relatively smaller number of innovators in Europe could be the clue as to why Europe is
falling behind the United States in terms of both publication and patents share. Indeed, the
number of scientific papers
5 produced by American players had reached 1,805 by 1996, of
which 760 (42%) were of academic origin, 501 (27%) from public and private non-profit
research centres and 285 (16%) and 259 (14%) from small and large firms respectively. In
addition, a patents count reveals that 878 (74%) patents were held by American
organisations
6, mostly small and large firms and, to a much lesser extent, by universities
and public institutions.
Meanwhile, the EU was placed a distant second with 913 scientific publications,
only slightly more than half the US contribution. Of these papers, 427 (46%) were from
universities, 373 (40%) from public and private non-profit organisations, 29 (3%) from
small firms and 84 (9%) from large, established companies. It is worth remarking, though,
that the publication growth rate attributed to European universities, estimated at 66%
between 1994 and 1996, significantly outpaced the overall growth rate of publications
                                                                                                                                                                                
4 Patents granted represent about 95% of patent applications.
5 While our scientific publication database comprised 2570 papers, 755 papers had been authored by 2 or
more parties. Hence the total number of identified authors is higher than 2,570, totalling 3,327 different
organisations.
6 Our EPO patent database includes 1165 patents, of which 21 were held by organisations from two or more
countries.12
produced by American universities, estimated at 49% for the same period. On the other
hand, European organisations did not fare better in terms of patents count, accounting for a
mere 234 (19% of total) patents, three time less than their American counterparts. Finally,
the rest of the world, which encompasses Australia, Canada, Hungary and Japan, ranked
third with 619 articles. Academia was responsible for 216 (34%) scientific publications,
public and private institutions 181 (29%), small firms 165 (26%) and large firms 57 (9%).
Research investigation also revealed that these countries, with 74 (6%) patents in all, lag
behind the US and the European Union in terms of patents count.
Turning to citations in patents in scientific publications, we only considered patent
applications up to 1994, a decision that was justified on the grounds that the data from EPO
is usually a few years behind. Therefore, citations to 816 combinatorial patents, which
covered the period 1986-1994, had to be extracted, and the data divided into CHI’s
classification whenever possible. To do this, we used the Science Citation Index (SCI)
database of the Institute for Scientific Information. Of the 816 patents identified, 621 had
non-patent citations, citing 2,521 publications. Unfortunately, 798 citations in patents to
journals were not covered by the SCI or belonged to older journals (1980 andearlier) that
were unavailable for analysis; thus, in this latter case, we only had the year of publication.
Finally, the year of publication was not available for 78 of the citations, preventing us from
finding any further information. As a result, we were only able to find the full
bibliographical information on the SCI database for 1,645 citations in 445 patents.
Empirical findings
Attesting to the rich variety of patterns across science-technology relationships,
combinatorial chemistry and biology innovations, akin to genetics, but less so than
chemistry and allied products, agricultural products, drugs and medicine and food kindred
products and even less so than transport equipment and textile products (see figure 2), are
shown to rely strongly on the scientific literature. Thus the results of our analysis reveal an
extremely high scientific content: of the cited papers, 80.7% belong to level 4 (i.e. basic
research), 17.6 % were in level 3 (i.e. applied research/clinical investigation) and the rest
(1.7%) in levels 1 and 2 journals (i.e.. applied technology and engineering and
technological sciences/clinical mix). Breaking down the patent data and the citations in13
scientific journals by type of innovations, the role played by science in the creation of
process innovations (86.0%) appears to be even more predominant than product innovation
(77.8%).
Whereas our findings may come as a surprise, it should be pointed out that
combinatorial synthesis approaches, which depend largely on the chemistry and application
of biological and chemical oligomers as well as decorated and modified biological
monomers, can be stifled by the inadequacies of existing building blocks, scaffolds,
reagents and solid support substrates. To put this another way, current knowledge in
medicinal chemistry cannot sustain hope for the combinatorial synthesis of all possible
chemical combinations. These technical difficulties are further compounded with regard to
process innovations as combinatorial synthesis takes place in miniaturised settings. Indeed,
small-scale equipment has become the single most important issue for combinatorial
applications because miniaturisation makes it possible to lower reagent costs, improve
analytical sensibilities and integrate chemical synthesis with other drug discovery steps
such as high-throughput screening and genomics (Borman 1998). One needs only to look at
the size of combinatorial libraries, which in exceptional cases can be made up of 1012
compounds, to appreciate the difficulties facing scientists with regard to the isolation and
identification of drug candidates. Attempts to circumvent this problem have been
successful, for instance, the discoveries of deconvolution methods and tag-encoding
technologies, but research along these avenue and many others is still proceeding apace
(Wells 1998). To sum up, these compelling needs have been a major challenge for
combinatorial chemists, who have responded by performing basic research activities to an
extent and at a level that has been rarely seen in the history of drug discovery.14
Figure 2: Linkage to science by product field
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% of references to basic research journals
Sources: (1) derived from Narin and Olivastro (1992); (2) derived from Collins and Wyatt (1988).
Of equal interest is that citations to biomedical research journals represented 63% of
total citations to papers, whereas the chemistry and clinical medicine journals were
responsible for only 19.9% and 16.1 % respectively of total patent references. It is also
worth pointing out that citations in patents to chemical literature increased by 22 percent
between 1991 and 1992, whereas biochemical citations decreased by 19 percent, reflecting
a shift away from the biochemistry knowledge base towards the chemistry discipline. A
major reason for this is that peptide libraries began to lose some of their appeal in favour of
libraries made of smaller chemical molecules (i.e. with molecular weight of about 500
daltons or less). This is because small chemical compounds, albeit more difficult to
assemble, give higher hit rates with more reactions to a particular target and, perhaps more
importantly, can be delivered orally (i.e. through tabletor other means) rather than
parenterally (i.e. by intravenous or intramuscular injections, through implantable pumps,
etc.)
7.. The trend which began in 1992 is generally attributed to a team of researchers led by
Bunin and Ellman of the University of California (Berkeley) which, after developing a
general combinatorial method, set up a library of compounds that had previously created a
broad spectrum of psychotropic drugs such as Hoffman LaRoche’s Valium® (Bunin and
                                                          
7 Peptides, when taken orally, become seriously vulnerable to digestive enzymes and often end up being
destroyed in the stomach and intestines before having the change to take effect. In this context, arguing that
small chemical compounds born out of combinatorial chemistry offer a technical and commercial advantage
makes perfect economic sense. The argument is further reinforced by noting that orally active medications, by
causing less discomfort and less inconvenience, can increase patient compliance and wider use, a human
reflex that may lead to larger markets and greater profits (Damms and Bains 1995).15
Ellman 1985). This group has since been emulated by competing researchers and the
method extended slowly to other small molecules such as carbohydrate molecules, l-
lactams, biphenyls, acylpiperidines and pyrrolidines (Eckker and Crooke 1995).
Two important and related propositions come out of these overall results. The first is
that the fields of combinatorial chemistry and biology owe a great deal to fundamental
research. Since combinatorial technologies tap intensively into the pool of generic
knowledge rather than merely embedding knowledge derived from applied research
programs, investments in fundamental research represent a sensible strategy for fostering
technical advances in the field. The second proposition is that patents related to
combinatorial synthesis methods and products heavily cite the biomedical, chemical and
clinical medicine literature journals. Therefore, if policy makers are resolved to support
combinatorial synthesis research activities in academic research systems, research efforts
should be directed towards the pharmacology, chemistry and biomedical chemistry
departments as they will offer the best potentials for generating knowledge spillovers in the
industry.
4. Science-technology linkages in combinatorial synthesis: A first look
In the previous section we focused our analysis on the scientific content of the citations to
the literature. Now, following the large body of literature that analyses the number of
citations in a patent as an indicator of the contribution of science to innovation, we examine
the relationships between the patent holder organisation and the organisation of affiliation
of the author of the paper.
On average, each patent cites 3 journal articles. Throughout the period under
consideration, patent citations show a static profile with a maximum number of citations in
1987 of 4.1 per patent, and a minimum in 1994 of 2.
8 The study by Grupp et al. (1995),
using comparable EPO data, identifies biotechnology as the technical area with the highest
number of citations per patent, i.e., between 2 and 2.5 in the period 1985-1992.
9 Thus,
                                                          
8 Narin and Olivastro (1998) emphasised that the occurrence of non-patent references appears to have been
relatively constant in the EPO system over the last decade.
9 Cited from Schmoch (1997).16
patents in combinatorial chemistry and biology show extremely high linkages with science.
Furthermore, the peak cited year for papers is 2 years prior to patent application which
represents an extremely short time-lag. Using US patents, Narin et al.. (1997) calculated
that the peak time for papers cited in drugs and medicine patents is 4-6 years prior to patent
grant. Therefore, even taking into account the granting period, the time lag in combinatorial
synthesis between scientific discovery and technological innovation tends to be very short.
The 1,645 publications for which institutional information was available account for
3,125 organisation addresses (about 1.9 authors per paper). Of these, 66% are from the US,
20.6% from the EU and 13.4% from other countries (including Japan 5.3%, Canada 3.0%,
and Australia and Switzerland about 1% each). The author institutions are classified as: (1)
universities, (2) research and other institutions, (3) small firms and (4) large firms (Table
1). Universities are the most often cited type of organisation; they account for 48% of total
citations. Research and other institutions, which includes, among others, hospitals, are the
author institutions in 33% of the citations. Finally, slightly less than 20% of citations are
shared equally between small and large firms. The 3,125 organisations addressed refer to
676 different institutions, 261 universities, 233 research and other institutions, 93 small
firms and 89 large firms respectively.
Table 1: Number of organisations and citations, by institution type





Research and other institutions 233 1,034
Small Firms  93 283
Large Firms 89 298
All Organisations 676 3,125
Table 2 shows the top 30 institutions in terms of number of citations. They account
for about 36% of the citations, with more than one-third being attributable to 4.4% of the
institutions. All are located in the US with the exception of the British Medical Research
Centre, the French CNRS and the University of Tokyo. Universities (with 18 institutions
among the first 30) are more than proportionally represented in the top group; not only do
they have the largest share of citations, but also they are the most often cited institutions.17
Cited research papers are authored principally at prestigious US universities. The top
university in the EU in terms of citations is the State University of Leiden in The
Netherlands with only 15 citations.  Public research centres, with five institutions among
the top 30 (2 European and 3 from the US), are the second most represented type of
institution.
The conclusions that can be drawn from the institutional analysis of citations to
literature are threefold. First, technological invention in the combinatorial synthesis
research platform relies heavily on the scientific discoveries made by non-profit
institutions, especially universities, and public research centres. In particular, US
universities are the most important source of reference for patents in combinatorial
synthesis. Second, scientific papers authored by researchers in small firms account for a
relatively relevant share of citations indicating the importance of the research developed by
these institutions (for instance, the case of Stratagene Cloning, Affymax and ISIS
Pharmaceutics). Finally, the citation distribution is highly skewed with 60 institutions
(about 9% of the total) accounting for more than half of the citations.
Table 2: Top 30 author institutions for number of citations on all patents
lbrdrtOrganisation Organisation type Country Frequency
HARVARD UNIVERSITY University US 125





NATIONAL CANCER INSTITUTION Public research centre US 122
UNIVERSITY OF  WASHINGTON University US 75
GENENTECH Large Firm US 66
MIT University US 48
PENN UNIVERSITY University US 42
MEDICAL RESEARCH COUNCIL Public research centre GB 42
UNIVERSITY OF CALIFORNIA AT SAN
FRANCISCO
University US 32
UNIVERSITY OF CALIFORNIA AT LOS
ANGELES
University US 27
STANFORD UNIVERSITY University US 26
UNIVERSITY OF  TOKYO University J 26
UNIVERSITY OF MICHIGAN University US 26
UNIVERSITY OF ALBERTA University US 24
US FOOD AND DRUG AGENCY Government agency US 24
UNIVERSITY OF CALIFORNIA AT SAN
DIEGO
University US 24
UNIVERSITY OF MISSOURI University US 23
UNIVERSITY OF CALIFORNIA AT
BERKELEY
University US 23




Public research centre US 22
BRIGHAM & WOMEN’S HOSPITAL Hospital US 21
MERCK SHARP & DOHME LTD Large Firm US 21
UNIVERSITY OF TEXAS University US 21
STRATAGENE CLONING SYSTEM Small Firm US 21
CALTECH University US 20
UNIVERSITY COLORADO University US 19
MASSACHUSETTS GENERAL HOSPITAL Hospital US 19
CNRS 1 Public research centre F 19
YALE UNIVERSITY University US 19
UNIVERSITY OF BAYLOR University US 18
One might wonder whether these results are affected by localisation in the process
of knowledge spillover (Jaffe, Trajtenber, and Henderson, 1993; Mansfield and Lee, 1996).
Narin et al. (1997) clearly showed that inventors cite their own countryuote s papers much
more than might be expected from their publication share in the SCI. First the citations to
papers from the country of the inventors compared to the total distribution of citation by
countries are analysed. For all countries, the number of citations to their own country’s
papers is higher than for all countries taken together. For the US this difference is small,
while for the EU countries the difference is much more significant. About 39% of the
citations to the literature in patents of the EU countries are to papers from institutions of the
EU countries. This share is almost double that for total patents. In the case of France,
Germany, Japan and the UK the ‘own country’ citations are three to four time higher than
for all countries combined. The reliance on ‘own country’ literature becomes extreme for
countries such as Italy and Canada for which more than 50% of the cited literature
originates in the author’s own country.
To confirm the relevance of localisation we have compared the share of ‘own
country’ citation to science papers with the share of publications by each country in
combinatorial synthesis (see Section 3 for the description of the combinatorial synthesis
publication database). As in the previous case, generally there is evidence of a higher
citation rate for ‘own country’ papers. For the US, however, the difference is marginal. As
in the previous case, inventors from the other countries considered cite local literature at
least twice as often. For example, the UK ranks second in terms of publications on19
combinatorial synthesis with about 7.4% of the total; however, approximately 23% of all
the science papers cited in UK patents are authored by employees of UK organisations.
Finally, we compared the country share of publications in the SCI with own country
citations. The results confirm a bias in favour of ‘local’ literature. In this case, also, US
inventors (with about 69% of own country citations) more often cite US literature than
would be expected from the share of US papers in the SCI (about 35-45% in the scientific
areas relevant to combinatorial synthesis).
The current analysis confirms that science-technology linkages in combinatorial
synthesis, as measured by the citations to the literature in patents, are affected by the
location of the organisations. The technological inventions of a country rely heavily on the
scientific discoveries made in that same country, especially in the universities and public
research centres.
5. Conclusions
This paper has provided a first exploratory analysis of science-technology linkages in
combinatorial chemistry and biology. To begin with, we presented a technical and historical
description of the development of combinatorial synthesis methods, showing that they have
created a new research platform for drug and new material discovery. Subsequently, using
three original databases on firms, patents and publications, we examined the main
characteristics of science-technology linkages in this research platform.
The results of the empirical analysis provide evidence that supports the following
conclusions. First, the predominance of patents citations to basic research journals supports
the view that technological invention in combinatorial synthesis is characterised by an
extremely high scientific content. In particular, biomedical research is the most significant
knowledge base of reference for combinatorial chemistry and biology patents, although
chemical literature has been increasing in relevance since the early 1990s. Second, as in the
case of biotechnology and computational chemistry (Orsenigo, 1989, Mahdi and Pavitt,
1997), the US lead in firm formation is paralleled by the dominant role played by US20
universities and research centres. We found some evidence that the EU countries are
catching up in terms of university publishing, while the number of new combinatorial
synthesis firms in Europe remain very small. Third, the inventive capacity of a country
heavily depends upon the strength of the underlying universities and public research
institutes. The innovation process of firms relies to a great deal upon research carried out by
universities and by public research centres of their own country. Finally, the analysis of
patent applications and patent citations underlines the importance of small firms in the
development of the combinatorial synthesis research platform. Not only are they patenting
in a significant way, but they also are producing important publications that are cited in
other patents.
The preliminary results of this study emphasise the significance of the contribution
of academic research to industrial innovation. This overall conclusion must be qualified
given the shortcomings inherent in the methodology adopted, such as the fact that citations
are insert by the inventor but also by the examiner of the patents. Nonetheless, the results of
innovation surveys, such as the Yale and PACE, confirm the fact that, in the pharmaceutical
and chemical industries, the research carried out by public institutes and universities is
considered by research managers to be extremely important for the innovative activity of
firms (Arundel et al., 1995; Geuna, 1999; Klevorick et al., 1996). Further detailed analysis
of the institutional network in combinatorial synthesis is required to develop a better
understanding of the micro mechanisms by which knowledge created in universities and
public research centres spills over into the knowledge creation processes of firms and other
institutions.21
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